β-Catenin activation synergizes with Pten loss and Myc overexpression in Notch-independent T-ALL

Blood

Volumn 122, Issue 5, 2013, Pages 694-704

  Kaveri, Deepika ^a   Kastner, Philippe ^a   Dembélé, Doulaye ^a   Nerlov, Claus ^b,c   Chan, Susan ^a   Kirstetter, Peggy ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Italy)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD4 ANTIGEN; CD8 ANTIGEN; CRE RECOMBINASE; DEXAMETHASONE; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; MYC PROTEIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR 7; PTEN PROTEIN, MOUSE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CELL MATURATION; CELL SURVIVAL; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; IRRADIATION; MOUSE; NONHUMAN; ONCOGENE MYC; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN INTERACTION; T LYMPHOCYTE; THYMOCYTE; WNT SIGNALING PATHWAY; ANIMAL; CELL DIFFERENTIATION; DRUG POTENTIATION; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MUTATION; PHYSIOLOGY; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; BETA CATENIN; CELL DIFFERENTIATION; GENE DELETION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, MYC; MICE; MICE, TRANSGENIC; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PTEN PHOSPHOHYDROLASE; RECEPTORS, NOTCH; T-LYMPHOCYTES; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84886376861     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471904     Document Type: Article

References (54)

1. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1(1):75-87.
2. Bergeron J, Clappier E, Radford I, et al. Prognostic and oncogenic relevance of TLX1/ HOX11 expression level in T-ALLs. Blood. 2007; 110(7):2324-2330.
3. Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell. 2011;19(4):484-497.
4. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-271.
5. Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 2011;25(2):83-90.
6. Callens C, Baleydier F, Lengline E, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012;30(16):1966-1973.
7. Zuurbier L, Petricoin EF III, Vuerhard MJ, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2012;97(9):1405-1413.
8. Seke Etet PF, Vecchio L, Bogne Kamga P, Nchiwan Nukenine E, Krampera M, Nwabo Kamdje AH. Normal hematopoiesis and hematologic malignancies: role of canonical Wnt signaling pathway and stromal microenvironment. Biochim Biophys Acta. 2013;1835(1):1-10.
9. Ellmeier W, Sawada S, Littman DR. The regulation of CD4 and CD8 coreceptor gene expression during T cell development. Annu Rev Immunol. 1999;17:523-554.
10. Okamura RM, Sigvardsson M, Galceran J, Verbeek S, Clevers H, Grosschedl R. Redundant regulation of T cell differentiation and TCRalpha gene expression by the transcription factors LEF-1 and TCF-1. Immunity. 1998;8(1):11-20.
11. Tiemessen MM, Baert MR, Schonewille T, et al. The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas. PLoS Biol. 2012; 10(11):e1001430.
12. Weerkamp F, Baert MR, Naber BA, et al. Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. Proc Natl Acad Sci USA. 2006;103(9):3322-3326.
13. Schilham MW, Wilson A, Moerer P, Benaissa-Trouw BJ, Cumano A, Clevers HC. Critical involvement of Tcf-1 in expansion of thymocytes. J Immunol. 1998;161(8):3984-3991.
14. Staal FJ, Meeldijk J, Moerer P, et al. Wnt signaling is required for thymocyte development and activates Tcf-1 mediated transcription. Eur J Immunol. 2001;31(1):285-293.
15. Ioannidis V, Beermann F, Clevers H, Held W. The beta-catenin - TCF-1 pathway ensures CD4(1)CD8(1) thymocyte survival. Nat Immunol. 2001;2(8):691-697.
16. Xie H, Huang Z, Sadim MS, Sun Z. Stabilized beta-catenin extends thymocyte survival by up-regulating Bcl-xL. J Immunol. 2005;175(12): 7981-7988.
17. Hossain MZ, Yu Q, Xu M, Sen JM. ICAT expression disrupts beta-catenin-TCF interactions and impairs survival of thymocytes and activated mature T cells. Int Immunol. 2008;20(7):925-935.
18. Koch U, Wilson A, Cobas M, Kemler R, Macdonald HR, Radtke F. Simultaneous loss of beta-and gamma-catenin does not perturb hematopoiesis or lymphopoiesis. Blood. 2008; 111(1):160-164.
19. Jeannet G, Scheller M, Scarpellino L, et al. Longterm, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gammacatenin. Blood. 2008;111(1):142-149.
20. Luis TC, Naber BA, Roozen PP, et al. Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell. 2011;9(4):345-356.
21. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol. 2006;7(10):1048-1056.
22. Lee PP, Fitzpatrick DR, Beard C, et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity. 2001;15(5):763-774.
23. Wielenga VJ, Smits R, Korinek V, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999;154(2):515-523.
24. Dumortier A, Jeannet R, Kirstetter P, et al. Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol. 2006;26(1):209-220.
25. dos Santos NR, Rickman DS, de Reynies A, et al. Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood. 2007;109(9):3972-3981.
26. Maillard I, Koch U, Dumortier A, et al. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. Cell Stem Cell. 2008;2(4):356-366.
27. Tago K, Nakamura T, Nishita M, et al. Inhibition of Wnt signaling by ICAT, a novel beta-catenininteracting protein. Genes Dev. 2000;14(14): 1741-1749.
28. Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 2008;8(8):784-804.
29. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc (Min/1) mice attenuates intestinal tumorigenesis. Cancer Res. 2008;68(10):3655-3661.
30. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12(10):1167-1174.
31. Siapati EK, Papadaki M, Kozaou Z, et al. Proliferation and bone marrow engraftment of AML blasts is dependent on b-catenin signalling. Br J Haematol. 2011;152(2):164-174.
32. Protin U, Schweighoffer T, Jochum W, Hilberg F. CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J Immunol. 1999;163(9): 4917-4923.
33. Rack KA, Delabesse E, Radford-Weiss I, et al. Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1998;23(3):220-226.
34. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509-1512.
35. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cellspecific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001;14(5): 523-534.
36. Guo Z, Dose M, Kovalovsky D, et al. Beta-catenin stabilization stalls the transition from doublepositive to single-positive stage and predisposes thymocytes to malignant transformation. Blood. 2007;109(12):5463-5472.
37. Guo W, Lasky JL, Chang CJ, et al. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 2008; 453(7194):529-533.
38. Guo W, Schubbert S, Chen JY, et al. Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci USA. 2011;108(4):1409-1414.
39. Yu S, Zhou X, Steinke FC, et al. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. Immunity. 2012;37(5):813-826.
40. Bonnet M, Loosveld M, Montpellier B, et al. Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood. 2011;117(24):6650-6659.
41. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell. 2004;6(5):497-506.
42. Weerkamp F, van Dongen JJ, Staal FJ. Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia. Leukemia. 2006; 20(7):1197-1205.
43. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012;122(10):3398-3406.
44. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157-163.
45. Soulier J, Clappier E, Cayuela JM, et al. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005;106(1):274-286.
46. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20(15):2096-2109.
47. Sharma VM, Draheim KM, Kelliher MA. The Notch1/c-Myc pathway in T cell leukemia. Cell Cycle. 2007;6(8):927-930.
48. Li X, Gounari F, Protopopov A, Khazaie K, von Boehmer H. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J Exp Med. 2008;205(12): 2851-2861.
49. Palomero T, Ferrando A. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma. 2009; 9(Suppl 3):S205-S210.
50. Hann SR. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol. 2006;16(4):288-302.
51. Hasserjian RP, Aster JC, Davi F, Weinberg DS, Sklar J. Modulated expression of notch1 during thymocyte development. Blood. 1996;88(3): 970-976.
52. Axelrod JD, Matsuno K, Artavanis-Tsakonas S, Perrimon N. Interaction between Wingless and Notch signaling pathways mediated by dishevelled. Science. 1996;271(5257):1826-1832.
53. Kim HA, Koo BK, Cho JH, et al. Notch1 counteracts WNT/b-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest. 2012;122(9):3248-3259.
54. Chao DT, Korsmeyer SJ. BCL-XL-regulated apoptosis in T cell development. Int Immunol. 1997;9(9):1375-1384.